Key result
Inclisiran is linked to ~66% LDL-C reduction at 1 year in advanced non-dialysis CKD.
Why the study?
Does inclisiran reduce LDL-C in patients with advanced non-dialysis CKD?
Observational (n=10)
No
Does inclisiran reduce LDL-C in patients with advanced non-dialysis CKD?
Answers are grounded in this paper and cite their sources.
Inclisiran provides marked and sustained LDL-C reduction with preserved renal function and a favorable safety profile in patients with advanced non-dialysis CKD.
Background and Aims Advanced chronic kidney disease (CKD; stages G4–G5 not on dialysis) is associated with very high cardiovascular risk, and lipid control is particularly challenging due to reduced statin efficacy and frequent intolerance. Inclisiran, a small interfering RNA (siRNA) that inhibits hepatic PCSK9 synthesis, has demonstrated sustained LDL-C reductions in clinical trials, though data in advanced CKD remain scarce. Materials and methods An observational, retrospective case series was conducted at a tertiary care hospital, including 10 patients with stage G4–G5 non-dialysis CKD and elevated LDL-C despite optimized therapy or with statin intolerance. Inclisiran was administered following the standard regimen (day 0, day 90, and every 6 months thereafter). Lipid profile, renal function, and albuminuria were assessed at baseline, 3–6 months, and 12 months. Results Patients had a mean age of 75 ± 5 years with high cardiovascular comorbidity. Baseline LDL-C was 131.6 ± 22.1 mg/dl, falling to 46.1 ± 26.5 mg/dl at 1 year (mean reduction 65.6%). All patients responded to treatment; 80% achieved LDL-C < 70 mg/dl and 60% achieved < 55 mg/dl. Renal function remained stable (eGFR 22.7 vs. 23.7 ml/min/1.73 m 2 ). A 27.4% reduction in median albuminuria was observed; however, all patients were receiving maximized nephroprotective therapy concurrently, and this finding should not be attributed to inclisiran. No adverse events or major cardiovascular events were recorded. Conclusions Inclisiran demonstrates a marked and sustained LDL-C reduction in patients with advanced CKD, with an excellent safety profile and preserved renal function, supporting its use in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Nanwani et al. (2026) conducted an observational in Advanced chronic kidney disease (stage G4-G5 non-dialysis) with elevated LDL-C (n=10). Inclisiran was evaluated on LDL-C reduction at 1 year (65.6% mean reduction). Inclisiran reduced mean LDL-C by 65.6% at 1 year in patients with advanced non-dialysis CKD, with stable renal function and no adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: